Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies

Mir Sohail Fazeli1, Vadim Khaychuk2, Keith Wittstock2, Boris Breznen1, Grace Crocket2,3, Mir-Masoud Pourrahmat1, and Leticia Ferri2

1Evidinno Outcomes Research Inc., Vancouver, BC, Canada. 2Bristol Myers Squibb, Princeton, NJ, USA. 3Joulé Inc., Edison, NJ, USA.

ABSTRACT

OBJECTIVE: To scope the current published evidence on cardiovascular risk factors in rheumatoid arthritis (RA) focusing on the role of autoantibodies and the effect of antirheumatic agents.

METHODS: Two reviews were conducted in parallel: A targeted literature review (TLR) describing the risk factors associated with cardiovascular disease (CVD) in RA patients; and a systematic literature review (SLR) identifying and characterizing the association between autoantibody status and CVD risk in RA. A narrative synthesis of the evidence was carried out.

RESULTS: A total of 69 publications (49 in the TLR and 20 in the SLR) were included in the qualitative evidence synthesis. The most prevalent topic related to CVD risks in RA was inflammation as a shared mechanism behind both RA morbidity and atherosclerotic processes. Published evidence indicated that most of RA patients already had significant CV pathologies at the time of diagnosis, suggesting subclinical CVD may be developing before patients become symptomatic. Four types of autoantibodies (rheumatoid factor, anti-citrullinated peptide antibodies, anti-phospholipid autoantibodies, anti-lipoprotein autoantibodies) showed increased risk of specific cardiovascular events, such as higher risk of cardiovascular death in rheumatoid factor positive patients and higher risk of thrombosis in anti-phospholipid autoantibody positive patients.

CONCLUSION: Autoantibodies appear to increase CVD risk; however, the magnitude of the increase and the types of CVD outcomes affected are still unclear. Prospective studies with larger populations are required to further understand and quantify the association, including the causal pathway, between specific risk factors and CVD outcomes in RA patients.

KEYWORDS: Rheumatoid Arthritis, cardiovascular diseases, risk factors, autoantibodies, disease modifying antirheumatic drugs

Introduction

A large body of evidence suggests patients with rheumatoid arthritis (RA) and other autoimmune inflammatory diseases face increased cardiovascular disease (CVD) risk.1 The precise scope of this increased risk is not clear: most current estimates indicate the range between 1.5 and 2 times higher than age- and sex-matched individuals from the general population.2 One of the main challenges in investigating the elevated CVD risk in RA is understanding the interplay between traditional and novel CVD risk factors with RA pathology itself.3

Although the prevalence of some traditional CVD risk factors is increased in patients with RA, extending the general population approach to CVD risk estimation in the RA population is flawed.4,5 For example, the most commonly used clinical instruments for estimating CVD risk scores, such as the Framingham Risk Score and the European SCORE system, underestimate CVD risk in RA by as much as 2-fold.2 The main reason for this discrepancy is related to the presence of novel CVD risk factors uniquely associated with RA progression and their synergy with traditional factors in elevating CVD risk.

Treatment history can change CVD risk assessment in RA patients with some treatment regimens having moderate effect on CVD risk, while the others show more pronounced effect.6–9 For instance, conventional therapies such as methotrexate (MTX) and glucocorticoids appear to have a modest cardio-protective effect.10,11 Recently introduced biologics and small molecule disease-modifying anti-rheumatic drugs (DMARDs) may decrease CVD risk,9 but the mechanism is poorly understood.6

A prominent clinical feature of seropositive RA is the presence of elevated levels of autoantibodies, including, but not limited to, rheumatoid factor (RF), anti-citrullinated peptide antibodies (anti-CCP), and others. The specific role of these autoantibodies in increasing CVD risk is still under investigation. Some studies have found that elevated RF levels do not...
predict increased CVD risk\textsuperscript{12} while other studies have found a direct link between increased RF levels and coronary heart disease.\textsuperscript{13} The presence of anti-CCP titer seems to be more directly related to increased CVD risk in RA\textsuperscript{14}; however, the contribution of specific citrullinated proteins to atherosclerotic processes is still under investigation.\textsuperscript{15}

Our objective was to describe the current landscape of published evidence on CVD risk in RA, including traditional and novel CVD risk factors, the association between autoantibodies and CVD risk in RA and the effects of antirheumatic therapies.

**Methods**

Two literature reviews were conducted in parallel. A targeted literature review (TLR) was conducted to identify risk factors and describe the effects of antirheumatic therapies on the development of CVD in RA patients. Doctor Evidence LLC’s proprietary search platform (DOC Search\textsuperscript{TM}), which contains MEDLINE\textsuperscript{®}, clinicaltrials.gov, WHO ICTRP, EPAR, Daily Med, and RSS feeds was used as the primary database for searches (date of search: from inception to January 2019). This was supplemented by a search of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) conferences for proceedings between 2017 and 2019.

A systematic literature review (SLR) was conducted to identify and characterize the association between autoantibody status and CVD risk in RA. Searches were performed on MEDLINE\textsuperscript{®}, Embase, and Cochrane CENTRAL (from inception to January 15, 2019). This was supplemented by a search of conference proceedings of the ACR and EULAR, as well as the United States and European Union clinical trial registries for entries on trials with results available (2017-2019).

Reference lists of previously published relevant SLRs were hand searched. Search strategies are presented in Supplemental Tables 1 to 3.

Screening for the TLR was guided by the Population, Intervention, Comparator, and Outcome (PICO) framework.\textsuperscript{16} Population for both reviews included adult patients with RA; in addition, for the TLR the criteria required presence of CVD comorbidities and for the SLR the evidence synthesis was stratified by autoantibodies status. Interventions and comparators were any or none. Outcomes in the TLR included CVD comorbidities, presence of CVD risk factors, any additional comorbidities, and mortality. For the SLR the outcomes included incidence, prevalence, and severity of cardiovascular diseases and cardiovascular events, stratified by autoantibody status.

The titles/abstracts were screened by a senior methodologist. Eligible studies proceeded to full-text screening phase where they were assessed for inclusion by the same methodologist. Articles deemed eligible at this stage were included in the qualitative evidence synthesis.

For the SLR, title/abstract and full-text screening was conducted by 2 senior methodologists. Discrepancies were identified and resolved by a third, independent investigator. Data extraction of the included studies was performed by the same 2 investigators in duplicate. Data extracted included study and patient characteristics, autoantibodies, therapeutic interventions and comparators, and the outcomes of interest. Quality control auditing was performed to ensure the accuracy and consistency of data across the dataset. The Cochrane Collaboration’s tool\textsuperscript{17} and Newcastle-Ottawa Quality Assessment Scale\textsuperscript{18} were used to assess the risk of bias in randomized studies and cohort studies, respectively.
Results
A total of 69 publications (49 via the TLR and 20 via the SLR) were eligible for inclusion in the narrative evidence synthesis. The selected publications in the TLR included 19 systematic literature reviews, 28 clinical studies (21 prospective and 7 retrospective) and 2 guidelines (EULAR and ACR). For the SLR, the 20 studies selected for data extraction included 7 prospective, 11 retrospective, and 2 cross-sectional. The PRISMA diagrams for both TLR and SLR are presented in Figure 1A and B, respectively.

CVD risk factors pre-RA diagnosis
Several recent studies noted that the risk factors of CVD often predate the onset of RA. The published literature highlights that many patients diagnosed with RA already have significant CVD pathologies at the time of diagnosis. In particular, atherosclerosis of carotid vasculature, which has an established causal relationship with CVD, seems to be present early in the natural history of the CVD. Lifestyle as well as prior history of smoking and obesity were associated with an increased likelihood of developing RA. In a case-control study of 547 pre-symptomatic patients in Sweden, Kokkonen et al found several CVD risk factors present in individuals years before the onset of the RA symptoms and that one-third of all the pre-symptomatic individuals had at least 3 factors present. Kerola et al examined subclinical cardiovascular changes in pre-RA population. Morphological evidence of arterial wall atherosclerosis was present during the first year following RA diagnosis suggesting the process started before the clinical diagnosis of RA itself. Davies et al who used carotid ultrasound to determine cardiovascular risk and prevalence of subclinical atherosclerosis at the time of diagnosis of RA, found that at the time of diagnosis, over 40% of the patients had either plaque or carotid intima-media thickness >0.9mm, both considered markers of high CVD risk. Van Boheemen et al followed a cohort of 594 consecutive arthralgia patients with positivity for RF and/or anti-CCP autoantibodies over a period of 10 years to assess the time point at which CVD risk increases prior to the RA diagnosis. The authors found that although dyslipidemia present in arthralgia patients predicted the development of RA, the differences in lipid profiles were too small to have an effect on the 10-year risk of CVD morbidity and mortality.

CVD risk factors post-RA diagnosis
Traditional CVD risk factors identified post-RA diagnosis largely overlaps with the CVD risk factors in the general population as follows:
- **Hypertension:** Following an RA diagnosis, hypertension appears to be more common among patients with RA compared to the general population. A population-based cohort study evaluating patients with newly diagnosed RA showed that if hypertension was present, the 10-year absolute risk of a CVD event rose significantly.
- **Insulin resistance and diabetes:** RA patients with type 2 diabetes are almost 2 times more likely to experience a CVD event compared with non-diabetic patients.
- **Obesity:** The body composition in RA patients seems to be different than in the general population, with lower muscle mass and higher percentage of fat (rheumatoid cachexia), particularly abdominal fat. This central obesity is associated with CVD risk factors in the RA population.
- **Smoking:** Smoking is an environmental factor associated with an increased risk of developing RA. Consistently, patients (particularly men) with RA seem to be more frequently smokers than individuals in the general population.
- **Dyslipidemia:** RA patients do not seem to have more hyperlipidemia than individuals in the general population, with low-density lipoproteins (LDLs), high-density lipoproteins (HDLs), and total cholesterol levels reduced in patients with active disease. These reduced lipid levels in RA patients are paradoxically associated with an increased CVD risk, and have been called the lipid paradox. A more detailed overview of this phenomena published recently noted a qualitative U-shaped relationship between patients’ lipid profile and CVD risk, where patients with the lowest LDL-C levels have higher CVD risk than those with moderate levels. Although the underlying mechanism for the altered lipid profile is unknown, some studies indicate that it is driven by the inflammatory process and is associated mainly with the increased cholesterol catabolism.
- **Hyperhomocysteinemia:** It is common among RA patients, as a consequence of the disturbance of homocysteine metabolism. In RA population it is influenced by immuno-inflammatory activation and resultant B vitamins deficiency and it is associated with increased CVD risks.

Novel CVD risk factors, those related to systemic pathological processes in RA and their relation to increased CVD risks, are as follows:
- **Inflammation:** Pro-inflammatory cytokines (specifically tumor necrosis factor alpha [TNF] and IL-6) implicated in RA have shown to enhance atherogenesis. Chronic inflammation is closely linked with atherosclerosis in RA: the burden of inflammation is associated with clinical and subclinical CVD, and positron emission tomography (PET) reveals arterial inflammation in patients with active RA.
- **Atherosclerosis:** Atherosclerosis is now recognized as a chronic inflammatory condition with involvement of pro-inflammatory cytokines inducing accelerated
atherosclerotic processes in RA population. RA and atherosclerosis share similar pathological processes. Under the influence of environmental factors, like smoking, some individuals develop an immune dysregulation where the endothelium allows the migration of inflammatory cells in the synovium, predominantly macrophages and T cells. Atherosclerosis occurs early in the course of RA. Laaper and Gabay hypothesized that chronic inflammation, particularly the involvement of TNF and IL-6, accelerates the progression of atherosclerosis. Although inflammation and atherosclerosis are known risk factors in the general population, in RA patients the persistent and systemic level of inflammation and atherosclerosis creates a novel and unique CVD risk profile.

- **Autoantibodies:** Currently, mostly RF and anti-CCP are utilized in clinical practice due to their acceptable sensitivities, specificities, and prognostic values. However, there is evidence that other autoantibodies may relate to RA and its CVD comorbidities. In the context of CVD, the 4 most investigated autoantibodies are: anti-CCP, RF; anti-phospholipid autoantibodies; anti-lipoprotein autoantibodies. Anti-CCP autoantibodies target citrullinated proteins and their presence is associated with coronary artery calcification, impaired left ventricular structure and function, lower left ventricular mass, stroke volume, and end diastolic volume shown by cardiac magnetic resonance imaging in rheumatoid arthritis. In addition, there is evidence for the link between anti-CCP autoantibodies and myocardial dysfunction due to the fact that the presence of citrullinated proteins in the myocardial interstitium is significantly increased in RA. The process of citrullination is an inflammation-dependent process and studies have demonstrated the presence of cit-fibrinogen and cit-vimentin within the inflamed atherosclerotic plaque. Moreover, there is a synergistic effect of RF and anti-CCP mediating RA-associated inflammation and disease activity. In addition to anti-CCP, recently the autoantibodies to carbamylated proteins (anti-CarP) have emerged as a particularly strong predictor of both prevalent and incident cardiovascular disease risk. Although anti-CarP autoantibodies can also be found in healthy individuals and in other rheumatic conditions, the prevalence of anti-CarP autoantibodies in RA patients is relatively high with specificity above 90%.

- **Psychological risk factors:** Patients with RA suffer from depression or anxiety more frequently than the general population. Depressed RA patients, without a history of CVD were found to be 40% more likely to have a heart attack as compared to those without depression.

- **Genetic risk factors:** CVD and RA share genetic and environmental risk factors, including polymorphisms in genes within the HLA region, smoking, and obesity. Genetic factors, including class II major histocompatibility antigens/human leukocyte antigens (HLA-DR), as well as non-HLA genes, have been implicated in the pathogenesis of RA. Shared epitope (SE) alleles, such as HLA-DRB1*01 and DRB1*04, some HLA alleles like HLA-DRB1*13 and DRB1*15 are connected to RA susceptibility. An advanced classification of SE categorizes SE alleles into 4 main groups namely, S1, S2, S3D, and S3P. The S2 and S3P groups have been linked to susceptibility of seropositive RA. Autoantibody responses in seropositive RA is regulated not only by HLA-DRB1*04 but also by at least 3 additional non-HLA genetic variants: PADI4, PTPN22, and CDK6.

**Effects of drug therapy on CVD risk in RA**

- **Statins:** The reduction of LDL cholesterol by statins leads to a significant decrease in major cardiovascular events in patients at either high or low risk for CVD, however the precise benefit of lipid lowering treatment in RA remains unclear. Although statins are associated with reduced CVD events and mortality in RA in primary prevention, in secondary prevention, after myocardial infarction, there was no statistically significant difference between RA or non-RA patients receiving statins.

- **Corticosteroids:** Low dose corticosteroid treatment regimen has a lowering effect on time-averaged disease activity, which is associated with a reduction in CVD risk. However, the results of a SLR reported conflicting evidence and found a poor association between low-dose corticosteroid exposure and CVD risk factors with a trend toward increasing major CVD events.

- **Methotrexate:** A 2015 meta-analysis found that MTX use was associated with a 21% lower rate of cardiovascular events compared with no MTX use (including use of other DMARDs or no DMARDs). In a landmark US-based cohort study of 5626 patients with RA, who were followed for up for 25 years, MTX therapy was associated with a 70% decline in overall mortality.

- **Biologic and targeted synthetic DMARDs:** Therapy with TNF alpha inhibitors appears to lower the likelihood of CVD in the RA population. This happens despite the increase of HDL cholesterol and an increase of fat in the abdominal/visceral region, most likely secondary to the improvement in the systemic inflammation. A similar improvement in CVD risk profiles has been seen with Janus kinase inhibitors. A review of 3 studies showed that abatacept in RA is associated with reduced risk of myocardial infarction compared to other
Association of autoantibodies with CVD in RA

Among the 20 references included in the SLR, 18 were published full-text articles and 2 were conference abstracts. This evidence base consisted of 7 prospective observational studies, 11 retrospective observational studies, and 2 cross-sectional studies. Definition of RA varied across the studies: 15 studies used the definition by ACR or EULAR criteria, 2 studies identified RA through medical records, 1 study included patients with self-reported RA, and 1 meeting abstract did not specify the RA definition. In all included studies, the risk of bias was low across all categories, indicating high-quality of the included studies (Supplemental Table 4).

Cardiovascular outcomes varied across studies. Total cardiovascular events or cardiovascular diseases were the most frequently reported outcomes, stratified by autoantibody status (n = 9), followed by cardiovascular death (n = 7). Other cardiovascular outcomes included stroke (n = 4), thrombosis (n = 4), coronary artery disease (n = 2), heart failure (n = 2), ischemic heart disease (n = 2), peripheral artery disease (n = 1), diastolic dysfunction or valvular lesions (n = 1), and thromboembolism (n = 1).

Four major types of autoantibodies were evaluated for their association with CVD risk in the RA population: RF, anti-CCP, anti-phospholipid, and anti-lipoprotein autoantibody status (Table 1). Ten studies reported cardiovascular outcomes stratified by RF autoantibody status. In RA patients, the presence of RF autoantibody was associated with a higher risk of total cardiovascular events or CVD, cardiovascular death, heart failure, and especially for patients who had recent or high dose exposure to glucocorticoids.

Seven studies reported cardiovascular outcomes stratified by anti-CCP autoantibody status. The presence of anti-CCP autoantibody was associated with a higher risk of ischemic heart disease, diastolic dysfunction, or valvular lesions. There was also a trend of higher risk of cardiovascular death for anti-CCP positive patients, but the difference was either not statistically significant or not tested for significance.

Four studies reported cardiovascular outcomes stratified by anti-phospholipid autoantibody status. The anti-phospholipid autoantibodies discussed include anti-cardiolipin, lupus anticoagulant, and general anti-phospholipid positive status defined by being positive for either of these 2 autoantibodies. The presence of anti-phospholipid autoantibodies, including anti-cardiolipin and lupus anticoagulant, were associated with a higher risk of thrombosis, especially arterial thrombosis. This finding is not surprising, since the association of these autoantibodies with thromboembolism has been found in other inflammatory and autoimmune rheumatic diseases. The mean prevalence of anti-phospholipid autoantibodies in RA has been found at 28% and the median was 22%. In a recently published systematic review, authors suggested that there are not enough data to support routine screening for antiphospholipid antibodies in RA, with a possible exception for pregnancy planning and thrombosis in the context a rheumatic disease.

Two studies reported cardiovascular outcomes stratified by anti-lipoprotein autoantibody status. The anti-lipoprotein autoantibodies discussed include anti-HDL and anti-Apo A1, a component of the HDL particles. The presence of anti-lipoprotein autoantibodies, including anti-HDL and anti-Apo A1, was associated with a higher risk of experiencing cardiovascular events.

Discussion

Our review contributes to the growing body of evidence of synergistic effects of traditional and novel CVD risk factors in RA patients. Our main goal was to review the cardiovascular and metabolic comorbidities in RA patients and summarize the current understanding of common mechanisms behind inflammation, atherosclerosis, and CVD diseases, in particular shared metabolic pathways involved in both pathologies. Similar emphasis on the role of inflammation can be seen in several recently published reviews. Lauper and Gabay surveyed recent advancements in the understanding of the interplay between inflammation and lipid metabolism in the development of atherosclerosis in the RA population. Skeoch and Bruce surveyed the role of inflammatory cytokines such as TNF alpha in modulating the traditional CVD risk factors as well as in directly impacting the vasculature. Common conclusion across these studies is that inflammation plays a crucial role in the pathogenesis of both accelerated atherosclerosis and RA and that inflammation has to be one of the targets of all therapeutic approaches.

From therapeutical point of view, it is important to note that changes leading to the increased CVD risk start long before the clinical manifestation of RA. It is now clear that some pathological processes predate the RA diagnosis. Subclinical changes in endothelial dysfunction and atherosclerosis have been documented early in the RA disease, suggesting that the processes started before the clinical RA diagnosis. In this context, it has been suggested that elevated level of RF plays the same role in increasing cardiovascular mortality risks in early stages of arthritis as it does in later stages of the disease. In fact, RF seropositivity in the absence of arthritis has also been shown to be associated with increased rates of cardiovascular mortality.
### Table 1. Studies reporting on CVD risks in RA patients.

| OUTCOME CATEGORIES | HAZARD RATIO (95% CI), INCIDENCE RATE, OR PROPORTION OF PATIENTS WITH CARDIOVASCULAR EVENTS/DISEASES DURING STUDY FOLLOW UP | AUTOANTIBODY POSITIVE VS NEGATIVE STATUS |
|-------------------|-------------------------------------------------------------------------------------------------|----------------------------------------|
|                   | RF (N=10)                                                                                       | ANTI-CCP (N=7)                         | ANTI-PHOSPHOLIPID (N=4) | ANTI-LIPOPROTEIN (N=2) |
| Total cardiovascular events or cardiovascular diseases (n=9) | 2/5 studies with significant results                                                              | 0/3 studies with significant results     | NR                      | 2/2 studies with significant results |
|                   | #1: 3.90 (95% CI: 1.99-7.65)* #2: 3.26 (95% CI: 1.86-5.71)*                                      | #1: 0.79 (95% CI: 0.23-2.85)           | Anti-HDL                |                           |
|                   | #3: 1.11 (95% CI: 0.79-1.57) #4: 13.4% vs 7.5%                                                  | #2: 16.02 vs 23.41 per 1000 PPy         | Anti-Apo A1             |                           |
|                   | #5: 17.6% vs 12.5%                                                                               | #3: 11.15% vs 8.22% P = .614           |                          |                           |
| Cardiovascular death (n=7) | 4/6 studies with significant results                                                               | 0/3 studies with significant results     | NR                      | NR                        |
|                   | #1: 1.30 (95% CI: 1.07-1.57)* #2: 1.73 (95% CI: 1.23-2.43)* #3: 1.62 (95% CI: 1.15-2.27)* #4: 2.82 (95% CI: 1.57-4.90)* #5: 1.18 (95% CI: 0.46-4.18) #6: 5.2 vs 4.2 per 1000 PPy |
| Stroke (n=4)      | NR                                                                                             | 0/2 studies with significant results     | 0/2 studies with significant results | Anti-cardiolipin (TNFi treated pts) | NR |
|                   | #1: 3.70 vs 4.78 per 1000 PPy #2: 4.4% vs 3.3% P > .05 #1: 3.70 vs 4.78 per 1000 PPy #2: 4.4% vs 3.3% P > .05 |
| Thrombosis (N=4)  | 0/1 study with significant results                                                               | 0/1 study with significant results      | 1/3 studies with significant results | Venous thrombosis | NR |
|                   | Arterial thrombosis #1: 5.4% vs 5% #1: 5.4% vs 5%                                               | Overall thrombosis #1: 5.2% vs 3.3% P > .05 |
|                   | #1: OR = 9.47 (95% CI: 1.82-49.12)* #2: 36.7% vs 3.6% #1: 0% vs 0.9% #2: 30% vs 0% |
|                   | Venous thrombosis Lupus anticoagulant #3: 20.0% vs 12.1%                                        |                          |                           |                           |

(Continued)
| OUTCOME CATEGORIES | HAZARD RATIO (95% CI), INCIDENCE RATE, OR PROPORTION OF PATIENTS WITH CARDIOVASCULAR EVENTS/DISEASES DURING STUDY FOLLOW UP | AUTOANTIBODY POSITIVE VS NEGATIVE STATUS |
|-------------------|---------------------------------------------------------------------------------|------------------------------------------|
|                   | RF (N=10)                         | ANTI-CCP (N=7)                           | ANTI-PHOSPHOLIPID (N=4) | ANTI-LIPOPROTEIN (N=2) |
|                   | #1: 6.8% vs 5%                     | #1: OR = 11.88 (95% CI: 1.98-71.30)      |                           |                          |
|                   |                                   | #3: 14.3% vs 0%                           |                           |                          |
| Coronary artery disease (N=2) | 0/1 study with significant results | 0/2 studies with significant results | NR | NR |
|                   | #1: 1.06 (95% CI: 0.83-6.39)       | #1: 9.17 vs 11.01 per 1000 PYY          |                           |                          |
|                   |                                   | #2: 9.5% vs 8.6%                          |                           |                          |
| Heart failure (N=2) | 1/1 study with significant results | 0/1 study with significant results | NR | NR |
|                   | #1: 3.29 (95% CI: 1.83-5.69)       | #1: 7.2% vs 6.4% P > .05                |                           |                          |
| Ischemic heart disease (N=2) | NR | 1/1 study with significant results | 0/1 study with significant results | NR |
|                   | #1: OR = 2.58 (95% CI: 1.17-5.65)  |                                           |                           |                          |
|                   | #1: 5.1% vs 1.2%                   |                                           |                           |                          |
| Peripheral artery disease (N=1) | NR | 0/1 study with significance | NR | Anti-phospholipid |
|                   | #1: 2.6% vs 0%                     |                                           |                           |                          |
| Diastolic dysfunction or valvular lesions (N=1) | NR | 1/1 study with significant results | NR | Anti-phospholipid |
|                   | #1: 72.2% vs 25.0% P = .011*       |                                           |                           |                          |
| Thromboembolism (thrombosis or embolism) (N=1) | NR | 0/1 study with significant results | NR | Anti-cardiolipin (TNFi treated pts) |
|                   | #1: RR = 2.7 (95% CI: 0.8-4.6)     |                                           |                           |                          |

Abbreviations: Anti-Apo A1, anti-apolipoprotein A1; Anti-CCP, anti-cyclic citrullinated peptide; Anti-HDL, anti-high density lipoprotein; CI, confidence interval; N, number of studies; NR, not reported; OR, odds ratio; PPy, person year; pts, patients; RA, rheumatoid arthritis; RF, rheumatoid factor; RR, relative risk; TNFi, tumor necrosis factor inhibitors.

Results are separated by the presence of autoantibodies.

*Subgroup of patients exposed to glucocorticoids within the latest 3 months.

*Statistically significant difference between autoantibody positive vs negative status; cells with at least 1 study showing statistically significant difference are also highlighted (no asterisk indicates lack of statistical significance or absence of P-value or CI).

*Labeling of unique studies within each cell.
It is therefore critical to identify these early risks and initiate appropriate treatment as soon as possible. The exacerbation of atherosclerosis during the course of RA progression is closely linked with chronic systemic inflammation; however, the precise mechanism leading to increased CVD risk is still under investigation. One possible explanation involves the link between the level of inflammation and the disease activity, which then, in turn, is strongly predictive of both CVD events and cardiac function. Clinical trials investigating arterial inflammation using FDG-PET imaging showed increased FDG aortic uptake in RA patients. The central role of the inflammation is also supported by the mitigative effects of anti-inflammatory treatment regimens on the CVD risk.

The double-impact of inflammation on both RA progression and increased CVD risk led some authors to suggest that treatment with biologic DMARDs (such as TNF alpha inhibitors) amounts to “killing 2 birds with 1 biological stone.” Currently ongoing TARGET trial (https://targetra.org) is aimed at understanding how different treatments for RA affect cardiac inflammation.

Joint evaluation of the role of autoantibodies in CVD risk assessment in our SLR is a novel contribution to the field. Considering the evidence reporting statistically significant difference between the autoantibody positive and negative patients, a few findings from this SLR warrant further evaluation. In RA patients, the presence of RF autoantibody was potentially associated with higher risk of cardiovascular death, heart failure, and total cardiovascular events or cardiovascular diseases, especially for patients who had recent or high dose exposure to glucocorticoids. The presence of anti-CCP autoantibody was potentially associated with higher risk of ischemic heart disease, diastolic dysfunction, or valvular lesions.

From a clinical perspective, this review suggests that presence of autoantibodies could potentially be associated with increased risk of specific cardiovascular outcomes, with different risk profile for different types of autoantibodies. For example, the hazard ratio for cardiovascular death between RF positive and RF negative patients was reported in 5 studies, with significant difference observed in 4 studies. No such ratio was observed in studies stratifying patients by anti-CCP status (see Table 1). Patients with anti-CCP seropositivity face increased risk of ischemic heart disease. Studies reporting on anti-phospholipid autoantibodies found significant risk increase of thrombosis (both arterial and venous) as well as stroke in seropositive patients. The increased risk of cardiovascular events associated with specific autoantibodies should be taken into consideration when deciding on a personalized treatment regimen.

A promising approach to analyzing the role of autoantibodies in RA is through genetic analysis. It is very likely that HLA-DR genes act indirectly through the regulation of autoantibody production involved in the development and outcome of RA. One potential explanation for inconclusive results with autoantibodies as described in the SLR is that the RA populations consist of several serological subphenotypes defined by polymorphisms outside the HLA-DRB1 locus.

To ensure high sensitivity and specificity of the findings, we followed recommendations from Cochrane Handbook for Systematic Reviews of Interventions. The review was focused on the most recent and relevant publications in clinical trial evidence, real-world setting, and systematic reviews therefore it did not summarize the trends over time. The goal was to capture current understanding of risk factors rather than produce an exhaustive survey of all published evidence. The review does not attempt to reconcile contradictory findings found in the literature or resolve open questions related to the relative role of CVD risk factors or the effects of therapy on CVD risk in RA. As such, it represents a snapshot of current evidence and the discussions related to the topic of CVD in RA.

Conclusion
Morbidity and mortality remain a major concern among RA patients due to increased risk of CVD. Traditional CVD risk factors, systemic inflammation, and RA disease-specific factors contribute to the accelerated risk of CVD in RA. This review suggests that the presence of autoantibodies may be associated with increased risk of specific CVD outcomes, with a different risk profile for different types of autoantibodies. The increased risk of cardiovascular events associated with autoantibodies, such as higher risk of cardiovascular death in RF positive patients, warrants further evaluation for clinical significance in RA patients. Studies in larger RA populations with a prospective design are required to further understand and quantify the association between specific risk factors and CVD outcomes in RA patients.

Acknowledgements
We would like to thank Yuting Kuang for her scientific input and work on parts of the project.

Author Contributions
Leticia Ferri and Mir Sohail Fazeli contributed to the study design and conceptualization; Boris Breznen and Mir-Masoud Pourrahmat carried out data configuration; Boris Breznen, Mir-Masoud Pourrahmat, and Mir Sohail Fazeli wrote and prepared the original manuscript draft; and Leticia Ferri, Vadim Khaychuk, Keith Wittstock, and Grace Crocket were responsible for reviewing and editing the final draft.

Ethics Approval and Consent to Participate
An Ethical Review Committee Statement was not applicable for this study.

Availability of Data and Materials
Not applicable. The data used for analysis was retrieved from openly published studies listed in our manuscript.
REFERENCES

1. Agca R, Heslinga SC, Rolleffstad E, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:57-28.

2. Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2017;27:136-140.

3. Charles-Schoeman C. Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep. 2012;14:455-462.

4. Skehos S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11:390-400.

5. Babaeva A, Kalininga EV, Zvonsorensko MS, Solodenkoiva KS, Osadchuk MA. Cardiovascular risk evaluation in long standing rheumatoid arthritis: real clinical data. Paper presented at: Annual European Congress of Rheumatology, EULAR. June 13-16, 2018, Netherlands.

6. Gloiolo A, Bissell LA, Buch MH. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. Expert Opin Drug Saf. 2018;17:697-708.

7. Kieh EH, Liao KP, Kim SC. Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis. Curr Rheumatol Rep. 2018;20:42.

8. Kraakman MJ, Dragoljevic D, Kammoun HL, Murphy AJ. Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. Clin Transl Immunol. 2016;5:e84.

9. Saitin M, Towheed T. The effect of TNF-α inhibitors on cardiovascular events in patients with rheumatoid arthritis: an updated systematic review of the literature. Curr Rheumatol Rev. 2016;12:208-222.

10. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036.

11. Soulaidopoulos S, Nikiforou E, Dimitroulas T, Kitas GD. The role of statins in cardiovascular risk evaluation in long standing rheumatoid arthritis: real clinical data. Paper presented at: Annual European Congress of Rheumatology, EULAR. June 13-16, 2018, Netherlands.

12. Higgins J, Green S. Handbook for Systematic Reviews of Interventions 5.1.0. Accessed October 18, 2018. http://handbook.cochrane.org

13. Charles-Schoeman C. Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep. 2012;14:455-462.

14. Gibbonsk PJ, Decker K, McDonald J. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14:R29.

15. Treharne GJ, Hale ED, Lyons AC, et al. Cardiovascular disease and psychological morbidity among rheumatoid arthritis patients. Rheumatology (Oxford). 2015;70:482-487.

16. Khimion LV, Klymsa IV, Naishetkin IM. Comorbidities and risk factors of cardiovascular diseases in rheumatoid arthritis patients [abstract]. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 14-17, 2017, Spain.

17. Prindahl J, Claussen J, Harlser-Petersen K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann Rheum Dis. 2013;72:1771-1776.

18. Bublaukt M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol. 2013;25:317-324.

19. Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2010;5:e100179922.

20. Crowson CS, Rolleffstad S, Idkalah E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77:48-54.

21. Lauper K, Gabay C. Cardiovascular risk in patients with rheumatoid arthritis. Semin Immunopathol. 2017;39:447-459.

22. Myasoedova E, Crowson CS, Kremers H, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-487.

23. Vongvanipou AD, Pellosco E, Vouliagm PV, Drossos A. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 2020;40:1181-1191.

24. Zanatta R, Colombo C, D’Amico G, D’Humières T, Dal Lin C, Tuna F. Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases. Int J Mol Sci. 2018;19:e80009.

25. Martens B, Tenenbein M, Golds M, et al. Cardiac magnetic resonance imaging: an important tool for monitoring cardiovascular risk in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;2021:202100149.

26. Barbhaiya M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an updated systematic review of the literature. Curr Rheumatol Rep. 2012;14:455-462.

27. Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;70:482-487.

28. Crowson CS, Rolleffstad S, Idkalah E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77:48-54.

29. Zanatta R, Colombo C, D’Amico G, D’Humières T, Dal Lin C, Tuna F. Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases. Int J Mol Sci. 2018;19:e80009.

30. Myasoedova E, Crowson CS, Kremers H, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-487.

31. Vongvanipou AD, Pellosco E, Vouliagm PV, Drossos A. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int. 2020;40:1181-1191.

32. Zanatta R, Colombo C, D’Amico G, D’Humières T, Dal Lin C, Tona F. Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases. Int J Mol Sci. 2018;19:e80009.

33. Martens B, Tenenbein M, Golds M, et al. Cardiac magnetic resonance imaging: an important tool for monitoring cardiovascular risk in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;2021:202100149.
50. Toussirot É. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis. Expert Opin Drug Saf. 2015;14:525-532.

51. Kim SC, Solomon DH, Rogers JR, et al. No difference in cardiovascular risk of tocolizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. 2018;48:399-405.

52. Barra LJ, Pope JE, Hinchon C, et al. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. Rheumatology (Oxford). 2017;56:768-776.

53. Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110:420-424.

54. Davis JM, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;56:829-830.

55. England BR, Sayles H, Michaud K, et al. Cause-specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:36-45.

56. Hejblum BP, Cui J, Luhey LJ, et al. Association between anti-citrullinated fibrinogen antibodies and coronary artery disease in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018;70:1113-1117.

57. Jacobsson LT, Turesson C, Hanson RL, et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum. 2001;44:1170-1176.

58. Jonsson T, Forsal J, van Vollenhoven R, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anti-cardiolipin antibodies. Ann Rheum Dis. 2004;63:1075-1078.

59. Kerola AM, Nieminen TV, Virta LJ, et al. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008. Clin Exp Rheumatol. 2015;33:391-398.

60. Kim KJ, Baek IW, Park KS, Kim WU, Cho CS. Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis. Lupus. 2017;26:88-94.

61. López-Longo FJ, Oliver-Miñarro D, de la Torre I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;60:419-424.

62. Mackey RH, Kuller LH, Deane KD, et al. Rheumatoid arthritis, anti-CCP positivity, and cardiovascular disease risk in the Women’s Health Initiative. Arthritis Rheumatol. 2015;67:2311-2322.

63. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-732.

64. Rodríguez-Carrio J, López-Mejías R, Alperri-López M, et al. PON activity is modulated by rs662 polymorphism and IgG anti-HDL antibodies in rheumatoid arthritis patients: potential implications for CV disease. Arthritis Rheumatol (Hoboken). 2016;68:1367-1376.

65. Seriolo B, Accardo S, Garnero A, Fasciolo D, Cutolo M. Anticardiolipin antibodies, free protein S levels and thrombosis: a survey in a selected population of rheumatoid arthritis patients. Rheumatology (Oxford). 1999;38:675-678.

66. Seriolo B, Fasciolo D, Sulli A, Cutolo M. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol. 2001;19:561-564.

67. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:70-75.

68. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Br J Rheumatol. 1995;34:606-609.

69. Vuilleumier N, Bas S, Pagano S, et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2010;62:2640-2650.

70. Helal A, Younis G, Huseini N, Elsharkawy E, Abdelbadi Abdelsadek N. Correlation between serum anti-citrullinated protein antibodies and subclinical cardiac affection in rheumatoid arthritis patients [abstract]. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 14-17, 2017, Spain.

71. Jauregui EA, Águedo CA, Aldana C, Muñoz YA. Cardiovascular risk, biologics and anti-cyclic citrullinated peptide positivity in rheumatoid arthritis [abstract]. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 14-17, 2017, Spain.

72. El Hashani G, Viola M, Sciascia S, Taher AT, Uthman I. Antiphospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence. Rheumatol Ther. 2021;8:81-94.

73. Olch E, Merrill JT. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep. 2006;8:100-108.

74. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010-2019.

75. Targóńska-Stepniak B, Piotrowski M, Zwolak R, Drellich-Zbroja A, Majdan M. Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis. Cardiovasc Ultrasound. 2018;16:18.

76. Geraldi-Pardilla L, Zartoshti A, Ozbek AB, et al. Arterial inflammation detected with 18F-fluorodeoxyglucose–positron emission tomography in rheumatoid arthritis. Arthritis Rheumatol. 2018;70:30-39.

77. Agca R, Blanken AB, van Sijl AM, et al. Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis. Rheumatology (Oxford). Published online January 14, 2021. doi:10.1093/ra/rtab107.

78. Anghel D, Panturu L., Jucut VC, et al. Evaluation of cardiovascular risk in patients with rheumatoid arthritis and anti-TNF-α therapy [abstract]. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 13-16, 2018, Netherlands.

79. Cacciaapaglia F, Fornaro M, Renna D, et al. The effect of 5-years B-DMARDs treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritis patients [abstract]. Paper presented at: Annual European Congress of Rheumatology, EULAR; June 13-16, 2018, Netherlands.

80. Barthom JM, Giles JT, Solomon DH. Editorial: tumor necrosis factor antagonists: killing two birds with one biologic stone. Arthritis Rheumatol. 2018;70:326-329.